Remibrutinib

Published

dm+d

Unassigned

New Medicines

Chronic spontaneous urticaria

Information

New molecular entity
Novartis
Novartis

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Highly selective, potent Brutons tyrosine kinase (BTK) inhibitor for oral administration [1,2]
The lifetime prevalence of chronic urticaria in the UK is 0.5–1%, but approximately 15% of people experience urticaria at some time in their lives [4].
Chronic spontaneous urticaria
Oral

Relapsing multiple sclerosis (MS)

Information

Licence extension / variation
Novartis
Novartis

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Highly selective, potent Brutons tyrosine kinase (BTK) inhibitor
MS estimated prevalence is 190 cases per 100,000 population. MS is more than twice as common in females than males. The highest prevalence for MS occurs in the 60 to 69 years age group for both sexes. The MS estimated incidence in England is between 8 and 11 new cases per 100,000 population [1].
Relapsing multiple sclerosis (MS)
Oral